Phase
Condition
Amyloidosis
Circulation Disorders
Treatment
Tafamidis
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Adult patients (age ≥18 years) with diagnosis of cardiomyopathy of wild type orhereditary transthyretin-mediated amyloidosis (ATTR-CM).
Patients to whom VyndaMx® Capsules is prescribed for the treatment of wild orhereditary ATTR-CM.
Exclusion
Exclusion Criteria:
Patient with hypersensitivity to VyndaMx® Capsule or to any of the excipients in theproduct.
Patients with rare hereditary problems of fructose intolerance.
Patient who has a contraindication to VyndaMx® Capsules according to the approvedlocal product label.
Study Design
Connect with a study center
Sri Jayadeva Institute of Cardiovascular Sciences and Research
Bangalore, Karnataka 560069
IndiaActive - Recruiting
AIG Hospital
Hyderabad, 500032
IndiaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.